Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis
- 19 November 2008
- journal article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 27 (1) , 110-113
- https://doi.org/10.1007/s00774-008-0001-2
Abstract
Langerhans cell histiocytosis (LCH) is a rare disease, probably an atypical myeloproliferative syndrome, with variable clinical presentation and behavior. In this report, we focus on bone involvement by LCH and treatment with zoledronic acid in six patients as they progressed after chemotherapy and radiotherapy. Zoledronic acid appeared safe and produced significant relief in pain.Keywords
This publication has 12 references indexed in Scilit:
- Skeletal Langerhans cell histiocytosis in children: Permanent consequences and health‐related quality of life in long‐term survivorsPediatric Blood & Cancer, 2008
- Langerhans cell histiocytosis in the maxillofacial area in adults. Report of three cases.2007
- Imatinib Mesylate for Cerebral Langerhans'-Cell HistiocytosisNew England Journal of Medicine, 2004
- Bisphosphonates: Clinical ExperienceThe Oncologist, 2004
- Bisphosphonates: Preclinical ReviewThe Oncologist, 2004
- Bisphosphonate Induces Remission of Refractory Osteolysis in Langerhans Cell HistiocytosisJournal of Bone and Mineral Research, 2002
- Atypical Cellular DisordersHematology-American Society Hematology Education Program, 2002
- Pamidronate for Bone Pain from Osteolytic Lesions in Langerhans'-Cell HistiocytosisNew England Journal of Medicine, 2001
- A randomized trial of treatment for multisystem Langerhans’ cell histiocytosisThe Journal of Pediatrics, 2001
- Treatment of Langerhans Cell Histiocytosis With PamidronateJournal of Pediatric Hematology/Oncology, 2001